Category: glaucoma
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
SAN FRANCISCO, CA--- This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit p
HONOLULU -- October 29, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Defi
SAN FRANCISCO -- Highlights of today's Scientific Program of the 2009 American Academy of Ophthalmology (AAO) - Pan-American Association of Ophthalmology (PAAO) Joint Meeting include: John T.
NEW YORK (October 21, 2009) -- A 50-year-old New York woman who was diagnosed with a progressive blinding disease at age 13 was implanted with an experimental electronic eye implant that has partially restored her vision. A team led by Dr. Lucian V.
SAN FRANCISCO, CA?Highlights of October's Ophthalmology, the journal of the American Academy of Ophthalmology, include good news on preserving vision in people with type 1 diabetes, a warning from the Cardiovascular Health Study for macular degeneration patients, and a report on how vision impacts well-being across the lifespan.
An international team, led by researchers from the University of California, San Diego School of Medicine and the National Eye Institute, has discovered gene variants for glaucoma in a black population. The finding could lead to future treatments or a cure for this disease, which leads to blindness in two million Americans each year.
Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of vision loss that results from blockages in the blood vessels in the retina, according to two reports in the September issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
Rockville, MD -- By 2020, 1.4 million Nigerians over age 40 will lose their sight, and the vast majority of the causes are either preventable or treatable, according to the Nigeria National Blindness and Visual Impairment Study Group.
A genetic search that wound its way from patients to mouse models and back to patients has uncovered an unlikely gene critically involved in a common birth defect which causes mental retardation, motor delays and sometimes autism, providing a new mechanism and potentially improving treatment for the disorder.
PHILADEPHIA -- July 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in chi
Taking eye drops multiple times a day can be difficult for patients to do, and because of blinking and tearing, as little as 1 to 7 percent of the dose is actually absorbed by the eye.
Hollywood, FL -- July 1, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).
SAN FRANCISCO, CA---The July issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes two studies that may influence clinical treatment of serious eye conditions.
SAN FRANCISCO, CA--- The June issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes new insights on why some corneal transplants fail, why some patients skip their glaucoma medications, and why preventing infections after LASIK is a growing concern.
